CCN2 Activates Cellular Senescence Leading to Kidney Fibrosis in Folic Acid-Induced Experimental Nephropathy
Cellular communication network factor 2 (CCN2, also known as CTGF) is a complex protein that regulates numerous cellular functions. This biomolecule exhibits dual functions, depending on the context, and can act as a matricellular protein or as a growth factor. CCN2 is an established marker of fibrosis and a well-known mediator of kidney damage, involved in the regulation of inflammation, extracellular matrix remodeling, cell death, and activation of tubular epithelial cell (TECs) senescence. In response to kidney damage, cellular senescence mechanisms are activated, linked to regeneration failure and progression to fibrosis. Our preclinical studies using a total conditional CCN2 knockout mouse demonstrate that CCN2 plays a significant role in the development of a senescence phenotype after exposure to a nephrotoxic agent. CCN2 induces cell growth arrest in TECs, both in the early phase and in the chronic phase of folic acid nephropathy (FAN), associated with cell-death/necroinflammation and fibrosis, respectively. Renal CCN2 overexpression was found to be linked to excessive collagen accumulation in tubulointerstitial areas, microvascular rarefaction, and a decline in renal function, which were observed three weeks following the initial injury. All these findings were markedly diminished in conditional CCN2 knockout mice. In the FAN model, injured senescent TECs are associated with microvascular rarefaction, and both were modulated by CCN2. In primary cultured endothelial cells, as previously described in TECs, CCN2 directly induced senescence. The findings collectively demonstrate the complexity of CCN2, highlight the pivotal role of cellular senescence as an important mechanism in renal injury, and underscore the critical function of this biomolecule in kidney damage progression.
Authors
- Marta Ruiz‐Ortega (ORCID: https://orcid.org/0000-0002-1495-6535)
- Raúl R. Rodrigues-Díez (ORCID: https://orcid.org/0000-0002-2456-6709)
- Sandra Rayego‐Mateos (ORCID: https://orcid.org/0000-0001-6874-2359)
- Roel Broekhuizen (ORCID: https://orcid.org/0000-0002-5495-9327)
- María Piedad Ruiz‐Torres (ORCID: https://orcid.org/0000-0003-1640-7326)
- Laura Márquez‐Expósito (ORCID: https://orcid.org/0000-0003-4812-1939)
- Roel Goldschmeding (ORCID: https://orcid.org/0000-0002-5471-1153)
- Alicia Villacampa (ORCID: https://orcid.org/0000-0002-7398-8545)
- Adrián M. Ramos (ORCID: https://orcid.org/0000-0003-2718-3591)
- Fátima Milhano Santos (ORCID: https://orcid.org/0000-0002-4041-1504)
- Concepción Peiró (ORCID: https://orcid.org/0000-0002-9690-7816)
- Alberto Ortíz (ORCID: https://orcid.org/0000-0002-9805-9523)
- Floris A. Valentijn (ORCID: https://orcid.org/0000-0003-3676-6596)
- Tri Q. Nguyen (ORCID: https://orcid.org/0000-0001-6475-0706)
- Lucía Tejedor-Santamaria (ORCID: https://orcid.org/0000-0003-4295-7284)
- Vanessa Marchant (ORCID: https://orcid.org/0000-0002-2767-0229)
- Sebastian N. Knoppert
- Antonio Battaglia-Vieni
Institutions
- Universidad Complutense de Madrid (ES)
- Universidad de Alcalá (ES)
- Heidelberg University (DE)
- Instituto de Salud Carlos III (ES)
- University Hospital Heidelberg (DE)
- University Medical Center Utrecht (NL)
- Escuela Nacional de Sanidad (ES)
- Hospital Universitario Fundación Jiménez Díaz (ES)
- Universidad Autónoma de Madrid (ES)
Publication Details
- Journal
- International Journal of Molecular Sciences
- Published
- 2025-05-06
- DOI
- https://doi.org/10.3390/ijms26094401
- Citations
- 2
- Primary Topic
- Connective Tissue Growth Factor Research
- Type
- article
- Field-Weighted Citation Impact
- 1.61
Funders
- Instituto de Salud Carlos III
- European Regional Development Fund